QUOTE AND NEWS
Market Intelligence Center  May 20  Comment 
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Akorn Inc. (AKRX) that should provide a 4.44% return in just 58 days. Sell one Jul. '15 call at the $40.00 level for each 100 shares of Akorn...
Wall Street Journal  Apr 27  Comment 
Generic-drug maker Akorn has run into accounting issues. In today’s frenzied deal market, though, that might attract interest.
TheStreet.com  Apr 27  Comment 
NEW YORK (TheStreet) -- Akorn shares are falling, down 20.62% to $43.85 on Monday, after the manufacturer of diagnostic and therapeutic ophthalmic pharmaceuticals amended its 2014 net revenue and pretax income figures after the closing bell on...
Clusterstock  Apr 27  Comment 
Akorn Pharmaceuticals screwed up its numbers, and now the stock is getting crushed. In a statement Friday, the company said there were errors in its financial statements for the financial year ending December 31 and the quarters ending June 30...
Benzinga  Apr 27  Comment 
Celladon Corp (NASDAQ: CLDN) shares dipped 78.95 percent to $2.88 on the failed CUPID2 trial of MYDICAR in advanced heart failure. Akorn, Inc. (NASDAQ: AKRX) shares declined 18.16 percent to $45.21 following the report of overstatement of...
newratings.com  Apr 27  Comment 
INDIANAPOLIS (dpa-AFX) - Actavis plc's (ACT) phase III study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections...
TheStreet.com  Apr 21  Comment 
NEW YORK (TheStreet) -- The shares of drugmaker Akorn  are rising after Israeli pharmaceutical company Teva  earlier today made a takeover bid for another company in the space, generic drugmaker Mylan  . WHAT'S NEW: Teva announced an $82...
Benzinga  Apr 15  Comment 
In a report published Wednesday, JP Morgan analysts initiated coverage of Akorn, Inc. (NASDAQ: AKRX) with a price target of $61. "Akorn is a niche generic manufacturer with capabilities in attractive, high barrier-to-entry markets (injectables,...
Benzinga  Apr 8  Comment 
Deutsche Bank issued a company note on Akorn, Inc. (NASDAQ: AKRX) initiating coverage on the company. Deutsche Bank rates Akorn as a Buy with a $55 price target. Analysts Gregg Gilbert and Greg Fraser wrote, "For a midcap specialty generics...





You may also be interested in articles related to Akorn (AKRX):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki